The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.
Philipp SchwablEva HambruchGrant R BudasPaul SupperMichael BurnetJohn T LilesManfred BirkelKsenia BrusilovskayaPhilipp KönigshoferMarkus Peck-RadosavljevicWilliam J WatkinsMichael TraunerDavid G BreckenridgeClaus KremoserThomas ReibergerPublished in: Biomedicines (2021)
The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis in NASH rats. While cilofexor seems to primarily decrease sinusoidal resistance in cirrhotic portal hypertension, the combination with propranolol additionally reduced mesenteric hyperperfusion.